There is a persistent myth in clinical operations planning that site activation takes about 4 months. Some sponsor timelines budget 3 months. Some internal project plans show 5 months with buffer. In practice, across a wide range of Phase 2 and Phase 3 trials, the median time from site selection to first patient screened is closer to 6 to 7 months, and for complex protocols or sites with high concurrent trial volume, it stretches further.
The gap between plan and reality is not new information. Clinical operations teams know it. What is less well understood is the distribution: where exactly do the months go, and which parts of the delay are within the control of the sponsor, the CRO, or the site?
The four segments of activation time
Site activation can be broken into four segments: site selection and feasibility, contract and budget negotiation, regulatory and IRB submission, and site initiation and readiness. Each has a planned duration and an actual duration, and the gap varies significantly between them.
Site selection and feasibility is typically the tightest to plan. Sponsor feasibility questionnaires go out, sites respond, and the sponsor makes a selection decision. This usually takes 4 to 8 weeks and tends to stay within that range. The variability here is mostly in site responsiveness, which is a function of how many concurrent trials a site is managing and how administrative burden at the site level has grown.
Contract and budget negotiation is where the first large variance appears. Planned duration is typically 6 to 8 weeks. Actual duration at many sites is 12 to 20 weeks. The reasons are familiar to anyone who has sat in a site management role: the site's legal department has a queue, the sponsor's budget template does not match the site's overhead structure, the indirect cost rate negotiation goes back and forth, and no one has authority to close the gap quickly. A study we looked at in late 2024 had a community oncology network site where the budget negotiation alone took 22 weeks, delaying first patient enrolment by nearly 4 months relative to the sponsor's project plan.
Regulatory and IRB: the layer teams plan worst
IRB submission and approval is the most commonly underestimated segment. A sponsor plan that shows "IRB: 4 weeks" is almost always optimistic. At sites using a central IRB, 4 to 6 weeks is achievable if the submission package is complete on first submission. But central IRB is not universal. Many academic sites use institutional review boards with full-board review cycles that meet monthly or bimonthly. A submission that misses a cycle waits until the next one.
Local IRB timelines also vary significantly by institution. Academic medical centers with high trial volumes have staffed IRB operations and tend to move faster than community hospitals with part-time review boards. When a trial network spans both types of sites, the slowest site sets the enrollment start date if the sponsor is waiting for full activation before opening enrollment.
Protocol complexity matters here too. A protocol with complex eligibility criteria, multiple treatment arms, or novel biomarker collection procedures will generate more IRB questions and revisions. We have seen first-in-class oncology protocols go through three or four IRB revisions before approval, adding 8 to 12 weeks to the regulatory segment alone.
Site initiation: the last mile that gets compressed
By the time contract and IRB delays have consumed the slack in a project plan, the site initiation visit and staff training are typically scheduled under time pressure. The site initiation visit (SIV) is supposed to train site staff, review the protocol, verify that the EHR is configured to capture required data points, and confirm that the site is genuinely ready to screen patients.
In practice, when the SIV is compressed because everything upstream ran long, two things happen. First, staff training is less thorough than it should be, which shows up later as protocol deviations during early enrollment. Second, EHR readiness issues that would have been caught at the SIV surface during the first few screening assessments, causing delays at exactly the moment when enrollment momentum should be building.
We have heard from coordinators at multiple sites that the SIV was completed with only 2 to 3 staff members present because the others were committed to other trials or had scheduling conflicts. The institutional knowledge from that SIV does not transfer efficiently, and the site ends up in a slow warm-up period during early enrollment that adds another 4 to 6 weeks before the site reaches normal screening pace.
What teams can actually control
Of the four segments, contract negotiation is the one where process changes have the most consistent impact. Sites and sponsors that maintain standard budget templates and have pre-negotiated indirect cost rates with their partner institutions move through contracting in 6 to 8 weeks reliably. Sites that treat each trial as a fresh negotiation from scratch spend 16 to 20 weeks on the same work.
Early regulatory preparation also compounds. Sponsors who push a draft IRB package to sites during feasibility, rather than waiting for contract execution, give sites the ability to start the submission process in parallel. This overlap can recover 6 to 8 weeks of sequential delay without changing any individual timeline.
The SIV compression problem is harder to solve by process alone. It requires sponsors to treat site initiation as a fixed-duration, non-compressible activity and to protect it in the project plan even when upstream delays have consumed buffer. That is a governance decision more than a process decision, and it requires sponsor project managers to push back against pressure to make up time in the last mile.
Where Enrollvue fits in the activation picture
We do not help with contract negotiation or IRB timelines. Those are outside the scope of what we do. Where we fit is at the transition from site activation to first patient screened: the moment when a site that has completed its SIV is ready to identify candidates and begin pre-screening.
The activation delays described above mean that sites often start screening with less warm-up time than planned, against a sponsor timeline that has already slipped. In that context, the ability to run a first-pass screen against the existing patient population quickly, rather than spending the first two to three weeks manually pulling charts, has a measurable effect on how fast the site reaches a steady enrollment pace.
The months lost in activation are real, and most of them are hard to recover. The weeks lost in early pre-screening are recoverable, and that is where we focus.